Top 3 drug approvals in oncology: April 2021

Written by Jade Parker, Senior Editor

oncology drug approvals

Over the past month, several oncology drugs have been newly approved; in this piece we provide you with the key facts to keep you up-to-date with the industry news. Trodelvy® (sacituzumab govitecan) Approved: 7 April 2021 Company: Gilead Sciences, Inc. (CA, USA) Indication: Metastatic triple-negative breast cancer and urothelial cancer At the start of the month Gilead Sciences gained approval from the US FDA for Trodelvy® (sacituzumab govitecan) to treat patients with unresectable, locally advanced or metastatic triple-negative breast cancer. The patients must have been treated with two or more prior systemic therapies, including at least one for metastatic disease....

To view this content, please register now for access

It's completely free